Axial Biotherapeutics is a biopharmaceutical company harnessing the link between the human gut microbiome and the central nervous system to develop a new class of biotherapeutics to improve the quality of life for people with neurological diseases and disorders.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/30/16 | $19,150,000 | Series A |
Domain Associates Heritage Medical Systems Kairos Ventures Longwood Fund | undisclosed |
| 06/20/19 | $10,000,000 | Venture |
Taiho Ventures | undisclosed |
